News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG announces recent payment decision by CMS

PDF Berlin (Germany) and Germantown, MD (U.S.A.), November 21, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) announced the Centers of Medicare & Medicaid Services(CMS) has changed their pricing determination for Epi proColon®, the first and only FDA-approved blood-based test for colorectal cancer (CRC) screening. In its recently published final payment determination for […]

Read more

Epigenomics AG: Appointment of Director Reimbursement and Medical Affairs

PDF Berlin (Germany) and Germantown, MD (U.S.A.), November 8, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) announced today that Nicholas T. Potter, PhD, FACMG has accepted the role of Director of Reimbursement and Medical Affairs effective November 1, 2017. Nick brings with him 25 years of experience in the delivery of MDx clinical […]

Read more

Supervisory Board of Epigenomics AG Appoints Dr. Jorge Garces as President and Chief Scientific Officer

PDF –Jorge Garces is a proven senior executive with deep technology and development expertise -Appointment underscores Epigenomics’ commitment to clinical, technical and operational excellence -New President and Chief Scientific Officer to join Epigenomics on December 1, 2017 Berlin (Germany) and Germantown, MD (U.S.A.), November 5, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the […]

Read more

Epigenomics AG issues convertible bonds

PDF Berlin (Germany) and Germantown, MD (U.S.A.), September 8, 2017 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY), or the “Company”, today announced that it has issued convertible bonds with a nominal value of EUR 7.1 million to Cathay Fortune International Company Limited (CFIC) excluding pre-emptive rights of existing shareholders. The issuance of the convertible bonds, […]

Read more

Epigenomics Commences Post Approval Study on Epi proColon®

PDF Berlin (Germany) and Germantown, MD (U.S.A.), August 30, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), today announced the initiation of a Post Approval Study (PAS), Performance of Epi proColon in Repeated Testing in the Intended Use Population (PERT) – NCT03218423. The PERT trial is being conducted in concert with the US […]

Read more

Epigenomics AG Announces 2017 Second Quarter and Six Months Financial Results

PDF -Reimbursement in the United States is a focus of the company as it will have the greatest impact upon commercial adoption of Epi proColon -The expected issuance of the convertible bond as agreed in the voluntary takeover offer will improve the financial position of the company with the addition of approximately EUR 6.5 million […]

Read more
...